Primus In News
Precision oncology gains ground as India clears targeted cancer therapies
25-12-2025
Nilaya Varma, Group CEO and Co-Founder,Primus Partners, highlights that the approvals represent a major step toward integrating outcome-based precision medicine into routine cancer care, with combination immunotherapies improving treatment outcomes for patient groups that previously had limited options.
Explore Related Insights
- Budget Reaction from Kanishk Maheshwari, Co-Founder & Managing Director, Primus Partners
- From tax reforms, energy security to financial inclusion: Expectations soar ahead of Union Budget
- Why the same show is now streaming on multiple OTT platforms
- Despite a challenging year, Gujarat’s textile industry may not see recovery anytime soon
